You are here: Industry Insights > Harbour BioMed

News List

Harbour BioMed Announces Dosing of First Patient of Two Phase I Trials for Next-Generation Anti-CTLA-4 Antibody HBM4003 prnasia
January 05, 2022
Harbour BioMed ("HBM", HKEX: 02142) announced that, its next generation anti-CTLA-4 fully human heavy-chain only antibody (HCAb), HBM4003, has completed the first dosing of first patient...
Harbour BioMed Announces Dosing of First Patient of Batoclimab Phase II Trial in Patients with Thyroid Eye Disease prnasia
October 20, 2021
Harbour BioMed ("HBM", HKEX: 02142) announced that, the clinical trial of its anti-FcRn antibody, batoclimab (HBM9161), has completed the first dosing of first patient in phase II trial for the treatment of thyroid eye disease (TED).
Harbour BioMed Announces Dosing of First Patient of Batoclimab Phase III Trial in Patients with Generalized Myasthenia Gravis prnasia
September 28, 2021
Cutting-edge health technology company, LifeWave, has solidified its place as one of America's fastest growing privately held companies by again making the Inc. 5000 list for 2021.
Harbour BioMed Appoints Yingying Chen, PhD, as Chief Financial Officer prnasia
July 21, 2021
Harbour BioMed announced the appointment of Dr. Yingying Chen as Chief Financial Officer (CFO). Dr. Chen will be responsible for leading the overall management of Finance & Investor Relations and overseeing all aspects of financial operations.
Harbour BioMed and Utrecht University Announce License Agreement with AbbVie and Initiation of COVID-19 Antibody Clinical Trials prnasia
December 15, 2020
Harbour BioMed (HBM), and Utrecht University (UU) today announced that they licensed to AbbVie their fully human, SARS-CoV-2 neutralizing antibody, 47D11 and program, for the prevention and treatment of COVID-19 and related coronaviruses, and that ...
Harbour BioMed Will Present Results From Its Phase II Clinical Trial with Tanfanercept (HBM9036) in Patients with Moderate-to-Severe Dry Eye Disease in China at the 25th Congress of Chinese Ophthalmol prnasia
November 17, 2020
Harbour BioMed (HBM) announced that the company will present the phase II clinical trial results of Tanfanercept (HBM9036) at the 25th Congress of Chinese Ophthalmological Society (CCOS) held in Xiamen from the 19th to 22nd November.
Harbour BioMed Announces Two China NMPA Clearances for Clinical Trials for Phase I & Combination Therapy of Next Generation Anti-CTLA-4 Antibody for Treatment of Solid Tumors prnasia
September 22, 2020
Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company announced approval of two Investigational New Drug (IND) applications by the China National Medical Products Administration (NMPA) of its next-generation fully human ...
Harbour BioMed Presented Pre-Clinical Data on A Fully Human Anti-CD73 Antibody at AACR Virtual Annual Meeting prnasia
July 16, 2020
Harbour BioMed (HBM), a global clinical stage biopharmaceutical company, today announced that the Company presented preclinical data from a fully human CD73 antibody (HBM1007) in an e-poster at the American Association for Cancer Research (AACR) Virtual A
Mount Sinai and Harbour BioMed collaborate to advance novel biotherapies to treat cancer and coronavirus COVID-19 pharmaceutical-business-review
March 12, 2020
Mount Sinai Health System and Harbour BioMed (HBM) have entered into a multi-year, multifaceted collaboration to develop novel, fully human antibodies for the treatment and prevention of various diseases including oncology and immunology.
Harbour BioMed gets FDA nod to begin clinical trial for HBM4003 in cancer pharmaceutical-business-review
March 06, 2020
Harbour BioMed has secured approval from the US Food and Drug Administration (FDA) to move ahead with clinical studies in the US for its anti-CTLA-4 antibody HBM4003 for the treatment of cancer.

Previous page 1 2 Next page